First proof-of-concept studies performed to investigate the therapeutic potential of our newly identified antibodies revealed that #5-CD38-IgG1 had comparable affinity and potent anti-myeloma activity to the clinically approved CD38 antibodies daratumumab and isatuximab. Here, CD38 is linked to plasma cell myeloma.